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Abstract
Background: Monoclonal antibodies are used extensively throughout the biomedical sciences for
detection of antigens, either in vitro or in vivo. We, for example, have used them for quantitation of
proteins on "reverse-phase" protein lysate arrays. For those studies, we quality-controlled > 600
available monoclonal antibodies and also needed to develop precise information on the genes that
encode their antigens. Translation among the various protein and gene identifier types proved non-
trivial because of one-to-many and many-to-one relationships. To organize the antibody, protein,
and gene information, we initially developed a relational database in Filemaker for our own use.
When it became apparent that the information would be useful to many other researchers faced
with the need to choose or characterize antibodies, we developed it further as AbMiner, a fully
relational web-based database under MySQL, programmed in Java.
Description: AbMiner is a user-friendly, web-based relational database of information on > 600
commercially available antibodies that we validated by Western blot for protein microarray studies.
It includes many types of information on the antibody, the immunogen, the vendor, the antigen, and
the antigen's gene. Multiple gene and protein identifier types provide links to corresponding entries
in a variety of other public databases, including resources for phosphorylation-specific antibodies.
AbMiner also includes our quality-control data against a pool of 60 diverse cancer cell types (the
NCI-60) and also protein expression levels for the NCI-60 cells measured using our high-density
"reverse-phase" protein lysate microarrays for a selection of the listed antibodies. Some other
available database resources give information on antibody specificity for one or a couple of cell
Published: 06 April 2006
BMC Bioinformatics 2006, 7:192 doi:10.1186/1471-2105-7-192
Received: 21 October 2005
Accepted: 06 April 2006
This article is available from: http://www.biomedcentral.com/1471-2105/7/192
© 2006 Major et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Bioinformatics 2006, 7:192 http://www.biomedcentral.com/1471-2105/7/192
Page 2 of 10
(page number not for citation purposes)
types. In contrast, the data in AbMiner indicate specificity with respect to the antigens in a pool of
60 diverse cell types from nine different tissues of origin.
Conclusion: AbMiner is a relational database that provides extensive information from our own
laboratory and other sources on more than 600 available antibodies and the genes that encode the
antibodies' antigens. The data will be made freely available at http://discover.nci.nih.gov/abminer
Background
Antibodies are used as tools throughout biomedical sci-
ence, and they are, increasingly, being incorporated into
clinical practice in such specialties as rheumatology,
oncology, and infectious diseases [1]. They are also find-
ing more and more application in the new high-through-
put biotechnologies such as antibody and protein lysate
microarrays [2-8]. As a consequence of that increased
prominence and range of application, antibody reagents
(particularly monoclonals) are being made available to
the researcher commercially in increasing numbers. How-
ever, some of them do not have the right affinity, specifi-
city, or other characteristics for a particular application,
creating a problem and, often, wasted effort for end-users
[8].
That was the case when our laboratory began the project
that motivated us to develop AbMiner: 'reverse-phase'
protein lysate microarray profiling of the 60 human can-
cer cell lines (the NCI-60) used since 1990 by the U.S.
National Cancer Institute's Developmental Therapeutics
Program to screen > 100,000 chemical compounds (plus
natural products) for anticancer activity [9,10]. In 2001,
Paweletz, et al. [11] introduced 'reverse phase' protein
lysate microarrays (henceforth, called 'lysate arrays' here),
in combination with laser capture microdissection and
robotic spotting technology. For the NCI-60 project, we
[12] then developed higher density lysate arrays that
incorporated all 60 cell lines plus controls, each at 10
serial two-fold dilutions to achieve wide dynamic range
and good reproducibility (17% coefficient of variation) in
profiling of protein levels across the cell types. Antibodies
were used to quantify protein on the arrays using a Cata-
lyzed Signal Amplification method (DAKO Cytomation,
Carpenteria, CA, USA). We obtained more than 600 com-
mercially available monoclonal antibodies to find ones
suitable for the purpose. Before application to the arrays,
we screened the antibodies by Western blot against a pool
of the NCI-60 lysates (equal amounts from each cell type).
Since the pool included cancer cell lines from 9 different
tissues of origin, it served as an extensive (though not
exhaustive) sampling of human protein antigens.
To record and monitor the validation process, we pro-
grammed a relational database that included the results as
well as correlative meta-data on each antibody reagent. It
became apparent, however, that the database (which we
later called AbMiner) would be valuable to a much
broader community of antibody users. We therefore
decided to develop it further as a public resource. For the
635 antibodies included to date, the user can browse the
information or search by antibody name or by any of 18
other features (Table 1). Although each investigator will
presumably want to vet antibodies for his or her particular
application, quality-control data and other information
in AbMiner can minimize time spent searching for usable
antibody reagents.
In addition, AbMiner provides a connection to other
'omic' data [13] by matching each antibody with the target
antigen's corresponding DNA and RNA identifiers. We
were initially motivated to translate antibody names to
gene symbols because of studies in which we were corre-
lating protein and mRNA expression from microarrays for
biomarker discovery [14]. The gene information in
AbMiner was later expanded to include a variety of
genomic and proteomic identifiers. Using our Match-
Miner program package [15], a tool for batch-translation
of identifiers, we matched each antibody to its antigen's
gene symbol. The corresponding gene name, UniGene
cluster ID, LocusLink ID, and RefSeq were then identified
using MatchMiner and other tools [15-22], with careful
manual curation. AbMiner provides link-outs from gene
identifiers to the corresponding entries in various public
resources (LocusLink, GeneCards, etc.), as well as to other
antibody databases. By providing a means to search by
DNA, RNA, or protein, AbMiner facilitates the integration
of genomic, transcriptomic, and proteomic information.
Construction and content
Antibody validation
Monoclonal antibodies directed against protein antigens
were obtained from many different commercial sources
(listed in the AbMiner program itself), with no particular
selection criteria except that antibodies directed against
very small (~ 10 kDa) or very large (> 350 kDa) proteins
were excluded. Species recognized included human,
mouse, rat, dog, chicken, frog, and others. Each vial of
antibody was assigned a unique AbMiner identification
code number so that screening of the particular vial could
be tracked. Pertinent information indicated in the schema
in Table 1 was also recorded.BMC Bioinformatics 2006, 7:192 http://www.biomedcentral.com/1471-2105/7/192
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Antibody screening and NCI-60 'reverse-phase' protein lysate microarrays Figure 1
Antibody screening and NCI-60 'reverse-phase' protein lysate microarrays. A) Sixteen 4-mm-wide nitrocellulose strips from a 
nitrocellulose membrane blot, each used to test a different antibody. Each blot was classified by the criteria described in the 
text. Asterisks indicate predominant band(s). Eight blots (53BP2, Brm, Btf, hCNK1, PTEN, Smad4, TIF2, and XPF) were classi-
fied as single band and the expected molecular weight. Four blots (HIF-1 α, IKK β, IKK γ, and pan-JNK) were classified as multiple 
bands. Two blots (CD54, and JNK pY185) were classified as wrong molecular weight. One blot (IGFBP-3) was classified as no 
band. All band results from this Western blotting were entered into AbMiner. It should be noted that the results in this figure 
may not correspond to the band results in AbMiner because the latter are sometimes updated after additional testing. B) Min-
iature incubation chambers for 4-mm strips used for incubations with primary and then secondary antibodies. C) Reverse-
phase lysate arrays. Each row consists of 10 two-fold dilutions of an NCI-60 cell line or a control pool consisting of all 60 cell 
lines. Concentrated pool was spotted at the bottom-right corner of each field to serve as a registration mark for image 
processing. i) lysate array stained for total protein with SYPRO Ruby. ii) lysate array incubated with an antibody for p300, a 
protein ubiquitously expressed in the NCI-60. iii) CDK2 expression across 60 cell lines. Only one cell line shows visible 
expression (arrow). Nonetheless, expression of CDK2 was still detected as a single band by Western blot iv) Negative control. 
The primary antibody was replaced by anti-Aspergillus niger glucose oxidase IgG1, which does not recognize any human antigen.
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To validate antigen-specificity by Western blot against a
wide range of human antigens, we harvested cell lysates
from each of the NCI-60 cell lines as described previously
[23,24] and generated a standard pool (NCI-60 pool)
containing approximately equal amounts of each of the
60 lines. Included in the pool were leukemias of several
lineages, melanomas, and cancers of breast, ovary, pros-
tate, colon, lung, kidney, and central nervous system.
After electrophoresis and blotting, each gel yielded 16
four-mm wide nitrocellulose strips, each of which was
used to screen a different antibody (Fig. 1a). To increase
the likelihood of detecting low-abundance proteins, we
loaded the gels quite heavily so that each small strip con-
tained 0.6–1.3 μg of pool protein. Up to 64 antibodies
were screened simultaneously by incubating each strip in
its own miniature incubation chamber (BioRad, Hercules,
CA, USA) (Fig. 1b).
The Western blot results were classified as follows: (a) sin-
gle band: one predominant band, at the expected molecu-
lar weight; (b) multiple bands: extra bands remaining with
a 5-second or longer film exposure; (c) wrong molecular
weight: predominant band or bands at unexpected molec-
ular weight(s); and (d) no band. Antibodies were Western-
blotted up to three or four times if required to obtain clear
results.
Table 1: Data fields in AbMiner. Fields that can be searched using AbMiner's Advanced Search function are indicated.
Fields in AbMiner Search Field
Antibody Information Antibody Name X
Molecular Weight Range/KDa X
Application(s) X
Species Reactivity X
Ig Isotype X
Immunogen Species X
Immunogen
Epitope
Monoclonal/polyclonal
Gene/Identifiers Gene Symbol X
Gene Name X
Symbol status
UniGene Cluster Id X
Entrez Gene Id X
RefSeq (mRNA) X
RefSeq (protein) X
Antibody Validation Validation Status
Band Result
Validation Date
Dilution Used
Product Information Vendor
Catalog no
Clone designation
Lot #
Concentration
Recommended start dilution
Summary of Western blot results for the first 441 antibodies  screened (and currently in AbMiner) Figure 2
Summary of Western blot results for the first 441 antibodies 
screened (and currently in AbMiner). The majority of anti-
bodies (71%) produced a single predominant band.
single band
71%
no band
3%
multiple band
25%
other
1%BMC Bioinformatics 2006, 7:192 http://www.biomedcentral.com/1471-2105/7/192
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We focused on Western blot analysis and designed the
screening process as we did because of the specific require-
ments for application of antibodies on reverse-phase
lysate arrays. Antibodies that recognize an epitope from
more than one protein (or isoform) can be used for detec-
tion and quantitation of proteins on a Western blot as
long as any extraneous bands have different effective
molecular weights and would show up as separate bands.
The lysate array, in contrast, is effectively a multiplexed
dot blot; the signal from each spot on the array is the sum-
mation of specific and non-specific binding of the anti-
body. Therefore, for the lysate arrays we used only
screened antibodies that produced a single predominant
band by Western at the expected molecular weight. How-
ever, antibodies that produced multiple bands may still be
useful for other applications, so information on them is
retained in AbMiner. Other types of quality control data
(for example, based on immunoprecipitation, immuno-
histochemistry, or flow cytometry) may be most pertinent
to other types of applications. AbMiner is extensible in
that data fields can be added to accommodate and present
such information.
As indicated in Fig. 2, approximately 70% of the commer-
cially available antibodies we screened produced a single
predominant band against the NCI-60 lysate pool; only
4% resulted in absent or questionable bands. Some anti-
bodies that produced a single band by Western blot were
expressed in only one or two cell lines out of the 60 on the
NCI-60 lysate arrays (Fig. 1c), indicating that the valida-
tion method is quite sensitive. Since each cell line pro-
vides about 1/60th of the pool's protein, we cannot rule
out the possibility that a relatively faint extraneous band
on the western would reflect a grossly incorrect target pro-
tein value for one or two cell types on the array. To check
that possibility would require doing 60 times as many
Westerns (or pools of small numbers of cell types per-
haps). In principle, that would be desirable, but the uncer-
tainties of the present quality control procedure are still
considerably less than those inherent in many other tran-
scriptomic and proteomic profiling technologies. As
noted previously, the user will presumably reassess candi-
date antibodies on his or her particular experimental sys-
tem in any case.
Gene information
AbMiner's Gene Information database provides transla-
tion among different data platforms and makes it possible
for the user to search by proteomic, transcriptomic, or
genomic identifiers. To find the intersection between data
sets from different platforms – such as cDNA [25,26] and
oligonucleotide microarrays [27]– one generally must
translate from one type of unique identifier to another
[15]. Finding an antibody that corresponds to a particular
gene can be problematic because many commercially
available antibodies do not have unique, universally used
names that represent the target gene product.
To match antibodies names with the appropriate identifi-
ers of the corresponding gene, we used MatchMiner [15].
MatchMiner translates among various gene and protein
identifier types, including HUGO name, common names,
aliases, chromosome locations, GenBank accession num-
bers, Affymetrix identifiers, and IMAGE clone IDs (Fig. 3).
For antibodies whose names could not immediately be
translated with MatchMiner, other resources were used to
Table 2: Identifiers matched to AbMiner antibodies and the number of antibodies with each identifier.
AbMiner Gene Information Records
Identifier Number of antibodies
Total antibodies in collection 635
Name (gene symbol) 513
Accession # (Refseq) 778
Unigene Cluster ID 522
Table 3: Antibodies in AbMiner with matching UniGene Cluster IDs in four microarray platforms
Number of antibodies in AbMiner that match microarray identifiers
Microarray Number of antobodies
Antibodies with UniGene IDs 635
Oligo 6.8 K 370
cDNA 430
U95 498
U133 515BMC Bioinformatics 2006, 7:192 http://www.biomedcentral.com/1471-2105/7/192
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cross-check and select the appropriate symbol [16-
22,28,29]. The gene symbols were then matched with the
other identifiers as described above. The final MatchMiner
output included the gene name and symbol, the HUGO
approval status of the symbol, mRNA and protein Ref-
Seqs, UniGene Cluster IDs, and LocusIDs. Through a
many-to-many relationship with the Antibody Informa-
tion File in AbMiner, any antibody can be associated with
its appropriate gene identifiers and vice versa. That feature
of AbMiner (see Table 1) facilitates navigation among
antibody, antigen, protein, DNA, and RNA data, allowing
for integration of information from disparate data sets.
System design and implementation
AbMiner is a relational database comprised of two major
components: (i) a data entry module constructed using
FileMaker Pro5.0™ (Santa Clara, CA USA) and used by our
team for data entry as well as for detailed tracking of the
antibody validation process.
(ii) a web application for sharing the various types of
information on antibodies, antigens, and genes with the
research community. The web application, written princi-
pally in Java, leverages a variety of available resources:
MySQL as the database engine; Hibernate to map the
objects into the database; JSP, Struts, and Tiles to render
the user interface; and JUnit and HTTPUnit for testing
individual programming units and the overall system. In
addition to providing the web user interface, we have
defined a simple HTTP specification that facilitates link-
age of other applications into AbMiner. The web applica-
tion was constructed under the "Agile Development"
paradigm, which encourages close, iterative interaction
between user/tester/motivators of the package (biologists)
and software engineers [30]. That interaction, and the
continuing revision of specs that the agile process encour-
ages, ensure that AbMiner will serve broad needs of bio-
logical researchers. It has been received enthusiastically in
extensive beta-testing.
Pipeline for matching antibodies to gene identifiers Figure 3
Pipeline for matching antibodies to gene identifiers. Antibodies were matched to corresponding gene symbols using Match-
Miner or a combination of other resources if the symbol was not immediately retrievable with MatchMiner. The translation 
from symbol to LocusID was obtained from the Human Genome Nomenclature Committee (HGNC). LocusLink ftp -down-
loadable files provided UniGene Cluster Ids and RefSeqs. We then used the LocusID to join to the HGNC file, after which all 
identifiers could be mapped back to the antibody originally input into MatchMiner. The often-complex, many-to-many relation-
ships between genes and antibodies are described in the text.
antibody name
MatchMiner
LocusLink
RefSeq
UniGene
HGNC
gene symbol
gene name
symbol status
RefSeq (mRNA + protein)
category
UniGene Cluster ID
LocusID
Antibody Information Gene Information
GeneCards
SwissProt
CGAP Gene Finder
PubMed
gene symbol
gene symbol
LocusID
RefSeq
UniGene Cluster ID
inexact match
AbMiner
data/information flow
many-to-many relationshipBMC Bioinformatics 2006, 7:192 http://www.biomedcentral.com/1471-2105/7/192
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Both components of AbMiner have the same underlying
model, which includes three main modules: Antibody,
Screening, and Gene. AbMiner uses a relational database
approach to manage the complex relationships among
those elements. The relationships are generally not one-
to-one. For example, a given gene often codes for different
splice variants, which may or may not be recognized by
the same antibody. Conversely, multiple antibodies from
different vendors or hybridoma clones may target a pro-
tein encoded by a single gene. An additional complication
is that, because of the continuing re-annotation of the
human genome, some identifiers are not unique or con-
stant. That dynamic process is exemplified by retired or
relocated UniGene clusters that can sometimes result in
more than one UniGene Cluster ID or LocusID entry for
the same gene. By constructing AbMiner as a relational
database, we have been able to organize and update those
one-to-many, many-to-one, and many-to-many relation-
ships.
Currently, AbMiner is populated with screening data gen-
erated by our own laboratory, but we plan to incorporate
data from other studies and repositories when available.
We also plan to put data entry pages on the web compo-
nent for input of screening information from other inves-
tigators in the research community who wish to
contribute (with appropriate attribution)
Screen shot of the AbMiner home page, at http://discover.nci.nih.gov/ Figure 4
Screen shot of the AbMiner home page, at http://discover.nci.nih.gov/. All search and browse links are shown, along with brief 
descriptions of each function. [Note to the Editor and Reviewers: The screen shot will be updated to reflect its content at the time of 
publication.]BMC Bioinformatics 2006, 7:192 http://www.biomedcentral.com/1471-2105/7/192
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AbMiner link-outs
The identifiers described in the last section perform an
additional function by serving as link-outs to their respec-
tive entries in LocusLink, UniGene, GeneCards, Entrez's
RefSeq, and our MedMiner program. AbMiner also pro-
vides links to the Mammalian Phosphorylation Resource
(MPR) [31], a web site that contains sequence informa-
tion for phosphorylation sites recognized with specificity
by commercial antibodies, and links to the Clinical Pro-
teomics Databank [32], which provides a list of phospho-
specific antibodies tested and used in the Clinical Pro-
teomics Program of the NCI. Other public and commer-
cial antibody databases, such as the Antibody Resource
page [33]and Abcam [34], are also linked. Finally,
AbMiner will serve as the central public database for an
antibody repository planned by the NCI Center for Cancer
Research (CCR).
Utility and discussion
AbMiner applied to molecular biomarker identification
As already noted, development of AbMiner was motivated
by our need to organize information on antibodies for
lysate array studies, and it has proved itself an almost
indispensable tool in that respect. Particularly important
is the information on the correspondence between anti-
body names, antigen names, and the variety of gene iden-
tifier types. We were able, for example, to address the
question of similarities and differences between mRNA
and protein expression profiles across the NCI-60 [12].
Identifiers of proteins quantitated on lysate arrays were
matched with identifiers of transcripts assessed on spotted
cDNA arrays (i.e., Image Clone Ids) and Affymetrix oligo-
nucleotide arrays (i.e., Affymetrix Ids) using MatchMiner
[15] and AbMiner. A central, unexpected finding was that
cell-structure-related proteins showed higher correlation
between protein and mRNA levels across the 60 cell lines
than did non-cell-structure-related proteins [12]. Using
the annotations and translation capabilities in AbMiner,
those analyses have now been extended to 89 proteins
detected on the lysate arrays by 154 different antibodies
(Shankavaram et al. manuscript in preparation).
We have also applied the resources of AbMiner to the
identification of molecular biomarkers at the protein
level. For one such study, we developed a multi-step "inte-
gromic" protocol [14,30], which included: (a) identifica-
tion of candidate markers using cDNA microarrays; (b) re-
sequencing of candidate clones; (c) corroboration of the
candidates' expression patterns from the cDNA microar-
ray using Affymetrix oligonucleotide chips; (d) protein
expression analysis using reverse-phase protein lysate
arrays; and (e) prospective validation of candidate
biomarkers on tissue microarrays consisting of hundreds
of tumor samples. With that algorithm we identified villin
and moesin as molecular markers that distinguish
between colon and ovarian adenocarcinomas. Those can-
cer types can be difficult to distinguish in a few percent of
metastatic or disseminated lesions in the abdomen, and
the differential diagnosis is important because it deter-
mines what drugs will be used for therapy. Our protocol
was successful in that case, but it depended on the availa-
bility and effective screening of quality antibodies for
identification of diagnostic markers at the protein level on
the lysate and tissue arrays. AbMiner gene identifiers will
help other investigators in similar searches for molecular
markers at the protein level, even when the search has
begun with genomic databases. Because AbMiner pro-
vides extensive information for over 600 validated anti-
bodies, the transcriptional signature of a gene can often be
corroborated directly at the protein level.
The protein-mRNA expression studies are continuing,
with promise. More than 500 of the 635 antibodies cur-
rently in AbMiner have UniGene Cluster IDs that match
those from four different NCI-60 microarray platforms
(see Table 2 and 3), providing a foundation for cross-com-
parison, for validation studies, and for hypothesis genera-
tion. AbMiner is contributing both to the selection of
antibodies and to the crucial link between protein and
transcriptional data.
Comparison with other antibody databases
AbMiner is certainly not the most comprehensive in terms
of numbers of antigens or antibodies covered. In that
regard, the classic source is Linscott's Directory [35]. The
Advanced Type Culture Collection (ATCC) [36] keeps list-
ings of large numbers of their available cell lines, includ-
ing hybridomas, and the Antibody Resource Page [33]
and Abcam [34] provide useful databases on antibodies.
AbMiner includes links to all of those sources. A number
of companies provide databases of the antibodies they
sell, but those will not be reviewed here. AfCS Signaling
Gateway provides [38] provides information on 138 pro-
teins (principally in the signaling pathways) and antibod-
ies against them. Western Blot quality control
information, generally on one or a few cell lines, is
included. Exactantigen [39] provides gene-specific and
species-specific information on antibodies, with links to
manufacturers' data sheets. The useful Human Protein
Atlas [40,41] features immunohistochemical images for a
variety of newly generated and other antibodies, comple-
menting the focus of AbMiner. There are also a number of
specialized antibody collections (e.g., on 3-D structures of
antibodies or on neurological or HIV-related reagents)
[42,43], but none that we have seen present ranges of
information similar to that of AbMiner. It would be well
beyond the scope of this article to review those databases,
but a number of them are described, with outlinks, by Lin-
scott's. AbMiner's database will continue to expand, butBMC Bioinformatics 2006, 7:192 http://www.biomedcentral.com/1471-2105/7/192
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not with the intention of competing with Linscott's in
coverage.
Overall, to the best of our knowledge, none of the other
sources have the range of information types on the anti-
bodies, the antigens, the vendors, and the antigen's genes
that AbMiner does, and none of them give the type of
multiple-tissue Western blot specificity data or protein
microarray data that are compiled in AbMiner. Insofar as
we have found, any Western blot results given in the other
databases had been obtained against single cell types. The
quality control criteria represented in AbMiner are stricter
and more comprehensive in that we have validated the
antibodies by Western blot against a pool representing a
wide range of cancer cell lines from nine different organs
of origin and from different cell lineages. Non-specificities
showed up in that more rigorous testing when they didn't
in testing against individual cell types.
AbMiner has unique relational characteristics for dealing
with the one-to-many, many-to-one, and many-to-many
relationships among antibody reagents, their antigens,
and the genes of those antigens. Through the use of
MatchMiner [15], supplemented by manual curation
from additional bioinformatic resources, AbMiner gives a
useful range of gene identifier types not otherwise easy for
the casual user to find. The Antibody Resource Page pro-
vides a listing of "databases/software" on immunological
reagents [33], but none of those listed have major overlap
with AbMiner in terms of their program and search capa-
bilities. We are currently using the structure of AbMiner as
template for an analogous database on siRNA reagents.
We developed AbMiner as we did to provide the type of
information needed for "integromic" [30,44] studies of
the type described above for biomarker identification –
that is, for the integration of different types of molecular
data at the DNA, RNA, protein, and functional levels. But
the program is also being found useful (in beta-testing) by
researchers with simpler aims: e.g., those who simply
want to find the right antibody for an assay.
Conclusion
AbMiner (Fig. 4) is a broadly useful, user friendly resource
for finding validated antibodies or for connecting anti-
bodies with gene identifiers and other types of genomic/
proteomic information. The user can browse or search by
multiple, full Boolean criteria for an antibody of interest
or look up corresponding antibodies from a list of genes
denoted by any of a variety of different identifiers. The
database is currently populated with > 600 available anti-
bodies plus information on their quality control and spe-
cificity against a pool of antigens from 60 diverse cell lines
in the NCI-60 panel. Also included are quantitative pro-
tein profiles across the NCI-60 cell lines for some of the
antibodies, as well as extensive antibody, protein, and
gene identifier translations and link-outs to a variety of
public bioinformatic resources. AbMiner will enhance the
ability of the research community to find suitable anti-
bodies and to link proteomics, transcriptomics, and
genomics in 'integromic' [30,44] studies.
Availability and requirements
AbMiner is freely accessible to both public and private sec-
tor users at http://discover.nci.nih.gov/abminer. Also
available there for batch downloading are the quality con-
trol results and lysate array data for screened antibodies.
They will be updated as new antibodies are tested [28].
Also available there is a detailed protocol for the Western
blot screening. Gene Information FILES will be updated
regularly. As a Java implementation, AbMiner is browser-
, operating system-, and platform-independent.
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